Telix and Merck to Commence Pan-Cancer Clinical Combination Studies
Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt,...
Read moreLatest News
Category: Clinical
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
Telix announces two new studies to evaluate the potential utility of TLX591-CDx and TLX250-CDx in breast...
Read more
Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®
Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being investigated in lung and ovarian...
Read more
Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
Telix announces Phase II academic study of TLX66 in children with high-risk...
Read more
First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer
Telix announces the first patient has been dosed in its ‘CUPID’ Phase I study of TLX592 in patients with advanced prostate...
Read more
ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update
Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer with Positron Emission Tomography...
Read more
First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
Telix announces that a first patient has been dosed in a Phase I study of TLX250-CDx in patients with bladder...
Read more
IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update
Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on study being planned in front-line...
Read more
TLX66 Meets Study Objectives in Patients with AL Amyloidosis
Telix announces bone marrow conditioning investigational candidate TLX66 has met study objectives, demonstrating the initial safety profile in patients with AL...
Read more
First Patient Dosed in Japanese Prostate Cancer Imaging Study
Telix announces the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product,...
Read more